Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2010

View Archived Issues

First oral anaphylatoxin C5a receptor antagonist CCX-168 is safe in phase I trial

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Preclinical studies evaluate Cz-007, Cz-008 and Cz-009 for treatment of Chagas' disease

Preclinical and first-in-human data reported on antimalarial OZ-439

ProStrakan provides update on Orexo's Abstral for cancer pain

GSK and Fiocruz expand collaboration to develop new drugs for tropical diseases

SUN-13837 accelerates functional recovery in rat models of spinal cord injury and stroke

FDA approves Vyvanse for ADHD in adolescents

Wyeth describes new PI3K-alpha/gamma and mTOR inhibitors

Isis and Xenon Pharma to develop hemojuvelin- and hepcidin-targeted drugs for anemia of inflammation

FDA grants orphan drug status to MP4CO for painful crises of sickle cell disease

Isotechnika and ILJIN to codevelop voclosporin for transplant indications

AtheroNova and Cedars-Sinai Heart Institute partner on treatment to reduce arterial plaques

Albert Einstein College of Medicine claims new Tim16 inhibitors

Infinity Pharma advances phase Ib/II IPI-926 trial in pancreatic cancer

InteRNA Technologies receives grant from Dutch government to develop miRNA-based therapeutics

Ono Pharma begins phase II trial of subcutaneous methylnaltrexone in Japan

ReNeuron treats first patient in phase I trial of ReN-001 stem cells in stroke

Lilly presents new inhibitors of 5HTT and NET

Angioblast Systems receives U.S. government grants for five stem cell projects

Janssen discloses new chemokine CCR2 receptor antagonists

Targeted Genetics enters agreement to acquire Biocontrol

Enrollment complete in ORACLE MS trial of cladribine tablets

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Phosphasgenics and 3M Pharma join to develop oxycodone pain patch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...